Trial NCT02923739

View at ClinicalTrials.gov 
Org. Study IDs: 2015-0647
Secondary IDs: 2015-0647 NCI-2016-01593

Last trial update was posted on 2024-03-13

MeSH Interventions

Albumin-Bound Paclitaxel Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Bevacizumab Endothelial Growth Factors Immunoglobulin G Immunoglobulins Paclitaxel

MeSH Conditions

Adenocarcinoma Adenocarcinoma, Clear Cell Adenocarcinoma, Mucinous Brenner Tumor Carcinoma Carcinoma, Endometrioid Carcinoma, Transitional Cell Cystadenocarcinoma Cystadenocarcinoma, Serous Recurrence

Other Conditions

Fallopian Tube Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Malignant Ovarian Brenner Tumor Ovarian Adenocarcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Stopping Reasons

The study was terminated early by the Sponsor

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID